Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade.

J Exp Clin Cancer Res · 2025 · PMC12649022 · PMID 41291775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although it did not reach statistical significance, the results may imply that SUP3 had better antitumor effects (Fig. 1 K).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.